Together, these results indicate that ApoE4-carriage is - independently of clinical diagnostic status - associated with AD-typical CSF amyloid and tau levels, as well as cognitive decline and neurodegeneration in the current ADNI sample. This evidence concerns the gene APOE and Mental deterioration.